Table 1. Demographics of HNSCC patient cohort.
| Patient characteristics | N (%) | |
|---|---|---|
| Gender | M | 55 (71) |
| F | 22 (29) | |
| Primary site | Oropharynx | 49 (64) |
| Hypopharynx | 28 (36) | |
| T-stage | T1 | 1 (1) |
| T2 | 13 (17) | |
| T3 | 35 (46) | |
| T4 | 28 (36) | |
| N-stage | N0 | 10 (13) |
| N1 | 7 (9) | |
| N2 | 52 (68) | |
| N3 | 8 (10) | |
| T-volumes | 0–30 cc | 38 (49) |
| >30 | 39 (51) | |
| Events | Death | 32 (42) |
| Locoregional Recurrence | 10 (13) | |
| HPV | positive | 21 (27) |
| negative | 56 (73) | |
| Smoker | current | 46 (60) |
| former | 19 (25) | |
| never | 4 (5) | |
| unknown | 8 (10) | |
| Alcohol consumption | yes | 47 (61) |
| former-alcoholic | 13 (17) | |
| never | 8 (10) | |
| unknown | 9 (12) | |
| Cisplatin regimen | daily (6 mg/m2, 5 weeks) | 17 (23) |
| 3-weekly (100mg/m2, 3×) | 46 (59) | |
| weekly (150 mg/m2, 4×) | 14 (18) | |
| Cumulative cisplatin dose | low (< 300 mg/m2) | 30 (39) |
| high (≥ 300 mg/m2) | 47 (61) | |
| time | ||
| Median age | at diagnosis | 58 years (SD = 9, 6) |
| Median survival | Overall survival | 63 months (SD = 39) |
| Locoregional control | 63 months (SD = 41) |
Pretreatment biopsy material from HNSCC tumors of 77 patients was sequenced and tested for functional repair associated FA/HR-variants, as determined in the cell line panel. All patients received concurrent cisplatin-based chemoradiotherapy, with some patients reaching a high cumulative cisplatin dose of ≥300 mg/m2.